Skip to main content
Top
Published in: BMC Public Health 1/2014

Open Access 01-12-2014 | Research article

Analysis of prices paid by low-income countries - how price sensitive is government demand for medicines?

Authors: Divya Srivastava, Alistair McGuire

Published in: BMC Public Health | Issue 1/2014

Login to get access

Abstract

Background

Access to medicines is an important health policy issue. This paper considers demand structures in a selection of low-income countries from the perspective of public authorities as the evidence base is limited. Analysis of the demand for medicines in low-income countries is critical for effective pharmaceutical policy where regulation is less developed, health systems are cash constrained and medicines are not typically subsidised by a public health insurance system

Methods

This study analyses the demand for medicines in low-income countries from the perspective of the prices paid by public authorities. The analysis draws on a unique dataset from World Health Organization (WHO) and Health Action International (HAI) using 2003 data on procurement prices of medicines across 16 low-income countries covering 48 branded drugs and 18 therapeutic categories. Variation in prices, the mark-ups over marginal costs and estimation of price elasticities allows assessment of whether these elasticities are correlated with a country’s national income.

Results

Using the Ramsey pricing rule, the study’s findings suggest that substantial cross-country variation in prices and mark-ups exist, with price elasticities ranging from -1 to -2, which are weakly correlated with national income.

Conclusions

Government demand for medicines thus appears to be price elastic, raising important policy implications aimed at improving access to medicines for patients in low-income countries.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ramsey FP: A contribution to the theory of taxation. Econ J. 1927, 37: 47-61. 10.2307/2222721.CrossRef Ramsey FP: A contribution to the theory of taxation. Econ J. 1927, 37: 47-61. 10.2307/2222721.CrossRef
3.
go back to reference Danzon PM, Towse A: Differential pricing for pharmaceuticals: reconciling access, R&D and patents. Int J Health Care Finance Econ. 2003, 3: 183-205. 10.1023/A:1025384819575.CrossRefPubMed Danzon PM, Towse A: Differential pricing for pharmaceuticals: reconciling access, R&D and patents. Int J Health Care Finance Econ. 2003, 3: 183-205. 10.1023/A:1025384819575.CrossRefPubMed
4.
go back to reference IMS Institute for Healthcare Informatics: The Global Use of Medicines: Outlook Through 2016. 2012, Norwalk: IMS Health IMS Institute for Healthcare Informatics: The Global Use of Medicines: Outlook Through 2016. 2012, Norwalk: IMS Health
5.
go back to reference DiMasi JA, Hansen RW, Grabowski HG: The price of innovation: new estimates of drug development costs. J Health Econ. 2003, 22 (2): 151-185. 10.1016/S0167-6296(02)00126-1.CrossRefPubMed DiMasi JA, Hansen RW, Grabowski HG: The price of innovation: new estimates of drug development costs. J Health Econ. 2003, 22 (2): 151-185. 10.1016/S0167-6296(02)00126-1.CrossRefPubMed
6.
go back to reference OFT: The Pharmaceutical Price Regulation Scheme. 2007, London: Office of Fair Trading, Report 885.OFT 2007 OFT: The Pharmaceutical Price Regulation Scheme. 2007, London: Office of Fair Trading, Report 885.OFT 2007
7.
go back to reference Schut FT, van Bergeijk PAG: International price discrimination: the pharmaceutical industry. World Dev. 1986, 14 (9): 1141-1150. 10.1016/0305-750X(86)90116-6.CrossRef Schut FT, van Bergeijk PAG: International price discrimination: the pharmaceutical industry. World Dev. 1986, 14 (9): 1141-1150. 10.1016/0305-750X(86)90116-6.CrossRef
8.
go back to reference Scherer FM, Watal J: Post-Trips Options for Access to Patented Medicines in Developing Countries, Commission on Macroeconomics and Health Working Paper Series. 2001, Geneva: World Health Organization, Paper No. WG4:1 Scherer FM, Watal J: Post-Trips Options for Access to Patented Medicines in Developing Countries, Commission on Macroeconomics and Health Working Paper Series. 2001, Geneva: World Health Organization, Paper No. WG4:1
9.
go back to reference Danzon PM, Furukawa MF: Prices and availability of pharmaceuticals: evidence from nine countries. Health Aff (Millwood). 2003, W3-521-W3-536. Suppl Web Exclusives: W3-521-36 Danzon PM, Furukawa MF: Prices and availability of pharmaceuticals: evidence from nine countries. Health Aff (Millwood). 2003, W3-521-W3-536. Suppl Web Exclusives: W3-521-36
10.
go back to reference Rojas M: Price differences in identical drugs across central American countries. J Pharmaceut Finance Econ Pol. 2005, 14 (1): 17-37.CrossRef Rojas M: Price differences in identical drugs across central American countries. J Pharmaceut Finance Econ Pol. 2005, 14 (1): 17-37.CrossRef
11.
go back to reference Danzon PM, Furukawa MF: International prices and availability of pharmaceuticals in 2005. Health Aff. 2008, 27 (1): 221-233. 10.1377/hlthaff.27.1.221.CrossRef Danzon PM, Furukawa MF: International prices and availability of pharmaceuticals in 2005. Health Aff. 2008, 27 (1): 221-233. 10.1377/hlthaff.27.1.221.CrossRef
12.
go back to reference Danzon PM, Mulcahy A, Towse AK: Pharmaceutical pricing in emerging markets: effects of income, competition, and procurement. Health Econ. 2013, doi:10.1002/hec.3013 Danzon PM, Mulcahy A, Towse AK: Pharmaceutical pricing in emerging markets: effects of income, competition, and procurement. Health Econ. 2013, doi:10.1002/hec.3013
13.
go back to reference Balasubramaniam K: Health and pharmaceuticals in developing countries: towards social justice and equity. 1996, Penang: Consumers International-Regional Office for Asia and the Pacific Balasubramaniam K: Health and pharmaceuticals in developing countries: towards social justice and equity. 1996, Penang: Consumers International-Regional Office for Asia and the Pacific
14.
go back to reference Myhr K: Comparing Prices Of Essential Drugs Between Four Countries In East Africa And With International Prices. 2000, Retrieved 1 April, 2007 Myhr K: Comparing Prices Of Essential Drugs Between Four Countries In East Africa And With International Prices. 2000, Retrieved 1 April, 2007
15.
go back to reference Maskus KE: Parallel Imports in Pharmaceuticals: Implications for Competition and Prices in Developing Countries, Final Report to the World Intellectual Property Organization (WIPO). 2001, Geneva: WIPO Maskus KE: Parallel Imports in Pharmaceuticals: Implications for Competition and Prices in Developing Countries, Final Report to the World Intellectual Property Organization (WIPO). 2001, Geneva: WIPO
16.
go back to reference Pitaknetinan K, Tangcharoensathien V, Supachutikul A, Bennett S, Mills A: Profit, payment and pharmaceutical practices: perspectives from hospitals in Bangkok. Health Policy. 1999, 46: 179-194. 10.1016/S0168-8510(98)00066-9.CrossRefPubMed Pitaknetinan K, Tangcharoensathien V, Supachutikul A, Bennett S, Mills A: Profit, payment and pharmaceutical practices: perspectives from hospitals in Bangkok. Health Policy. 1999, 46: 179-194. 10.1016/S0168-8510(98)00066-9.CrossRefPubMed
17.
go back to reference Frank RG, Salkever DS: Pricing, patent loss and the market for pharmaceuticals. Southern Econ J. 1992, 59: 165-179. 10.2307/1060523.CrossRef Frank RG, Salkever DS: Pricing, patent loss and the market for pharmaceuticals. Southern Econ J. 1992, 59: 165-179. 10.2307/1060523.CrossRef
18.
go back to reference WHO/HAI: Price, Availability And Affordability: An International Comparison Of Chronic Disease Medicines. 2006, Geneva: Health Action International WHO/HAI: Price, Availability And Affordability: An International Comparison Of Chronic Disease Medicines. 2006, Geneva: Health Action International
19.
go back to reference Russo G, McPake B: Medicine prices in urban Mozambique. A public health and economic study of pharmaceutical markets and price determinants in low-income settings. Health Policy Plan. 2010, 25 (1): 70-84. 10.1093/heapol/czp042.CrossRefPubMed Russo G, McPake B: Medicine prices in urban Mozambique. A public health and economic study of pharmaceutical markets and price determinants in low-income settings. Health Policy Plan. 2010, 25 (1): 70-84. 10.1093/heapol/czp042.CrossRefPubMed
20.
go back to reference Levison L, Laing R: The hidden costs of essential medicines. Essential Drugs Monitor. 2003, 33: 20-21. Levison L, Laing R: The hidden costs of essential medicines. Essential Drugs Monitor. 2003, 33: 20-21.
21.
go back to reference World Bank: World Bank Development Indicators. 2005, Washington DC: World Bank World Bank: World Bank Development Indicators. 2005, Washington DC: World Bank
22.
go back to reference Morel CM, McGuire AJ, Mossialos EM: The level of income appears to have no consistent bearing on pharmaceutical prices across countries. Health Aff. 2011, 30 (8): 1545-1552. 10.1377/hlthaff.2010.0317.CrossRef Morel CM, McGuire AJ, Mossialos EM: The level of income appears to have no consistent bearing on pharmaceutical prices across countries. Health Aff. 2011, 30 (8): 1545-1552. 10.1377/hlthaff.2010.0317.CrossRef
23.
go back to reference WHO: The World Medicines Situation. 2004a, Geneva: World Health Organization WHO: The World Medicines Situation. 2004a, Geneva: World Health Organization
24.
go back to reference WHO: WHO Medicines Strategy: Countries at the Core 2004-2007. 2004b, Geneva: World Health Organization WHO: WHO Medicines Strategy: Countries at the Core 2004-2007. 2004b, Geneva: World Health Organization
25.
go back to reference Babar Z, Scahill S: Is there a role for pharmacoeconomics in developing countries?. Pharmacoeconomics. 2010, 28 (12): 1069-1074. 10.2165/11584890-000000000-00000.CrossRefPubMed Babar Z, Scahill S: Is there a role for pharmacoeconomics in developing countries?. Pharmacoeconomics. 2010, 28 (12): 1069-1074. 10.2165/11584890-000000000-00000.CrossRefPubMed
26.
go back to reference Wirtz V, Forsythe S, Valencia-Mendoza A, Bautista-Arredondo S: Factors influencing global antiretroviral procurement prices. BMC Public Health. 2009, 9 (S6): S6-CrossRefPubMedPubMedCentral Wirtz V, Forsythe S, Valencia-Mendoza A, Bautista-Arredondo S: Factors influencing global antiretroviral procurement prices. BMC Public Health. 2009, 9 (S6): S6-CrossRefPubMedPubMedCentral
27.
go back to reference Seiter A: A Practical Approach to Pharmaceutical Policy. 2010, Washington DC: World BankCrossRef Seiter A: A Practical Approach to Pharmaceutical Policy. 2010, Washington DC: World BankCrossRef
28.
go back to reference Waning B, Kyle M, Diedrichsen E, Soucy L, Hochstadt J, Bärnighausen T, Moon S: Intervening in global markets to improve access to HIV/AIDS treatment: an analysis of international policies and the dynamics of global antiretroviral medicines markets. Global Health. 2010, 6: 9-10.1186/1744-8603-6-9.CrossRefPubMedPubMedCentral Waning B, Kyle M, Diedrichsen E, Soucy L, Hochstadt J, Bärnighausen T, Moon S: Intervening in global markets to improve access to HIV/AIDS treatment: an analysis of international policies and the dynamics of global antiretroviral medicines markets. Global Health. 2010, 6: 9-10.1186/1744-8603-6-9.CrossRefPubMedPubMedCentral
Metadata
Title
Analysis of prices paid by low-income countries - how price sensitive is government demand for medicines?
Authors
Divya Srivastava
Alistair McGuire
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Public Health / Issue 1/2014
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/1471-2458-14-767

Other articles of this Issue 1/2014

BMC Public Health 1/2014 Go to the issue